Abu Dhabi Global Healthcare Week Partners with Digital Health New York to Boost Digital Health Ecosystem

By HEOR Staff Writer

October 8, 2023

Unifying Efforts for Digital Health Ecosystem Globally

Abu Dhabi Global Healthcare Week (ADGHW) has partnered with Digital Health New York (DHNY) to enhance the global digital health ecosystem. The Memorandum of Understanding (MoU), signed on October 4, 2023, aims to promote collaboration, innovation, long-term investment, and knowledge exchange in the digital health sector.

The two-year partnership will focus on developing research and innovation in digital health, enhancing credibility in science, and providing access to subject-matter experts through open dialogue.

Tackling Global Healthcare Challenges through Digital Tools

The partnership comes at a time when global healthcare demands require collaboration and access to digital tools. Both ADGHW and DHNY are committed to supporting ongoing research and development initiatives, particularly in genomics, preventative and predictive medicine.

H.E. Dr. Ahmed Alkhazraji, Executive Director, Strategy and Policy at the Department of Health – Abu Dhabi and Bunny Ellerin, Co-Founder & CEO, DHNY, signed the partnership. The collaboration aims to leverage both parties’ rich networks to access long-term investment and forge partnerships in the global digital health arena.

ADGHW and DHNY also emphasise the importance of scientific credibility in the healthcare industry and are joining forces in collaborative research studies and the creation of scientific literature.

Reference url

Recent Posts

Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Patients

By HEOR Staff Writer

December 16, 2025

Accelerating Review for Transformative Multiple Myeloma Therapy The U.S. Food and Drug Administration (
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggressive Prostate Cancer
AKEEGA BRCA2 Approval Ushers in Precision Era for mCSPC The AKEEGA BRCA2 approval by the U.S. Food and Drug Administration (FDA) on December 12, 2025, represents a breakthrough for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). Johnson & Johnson...
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicines Lifecycle

By HEOR Staff Writer

December 9, 2025

In the pharmaceutical industry, AI governance in pharmaceuticals is crucial for harnessing artificial intelligence's potential in drug discovery, clinical trials, and patient monitoring. How can pharma companies integrate AI ethically across the medicines lifecycle? This article draws on a recent...